Ms Wagner
Module 1: Clinical Presentation and Prognosis of PAD; Recent Advances in Up-Front Treatment for Metastatic PAD
Park W et al. Pancreatic cancer: A review. JAMA 2021;326(9):851-62. Abstract
Stoffel EM et al. Pancreatic cancer: Changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology 2023;164(5):752-65. Abstract
Module 4: Role of PARP Inhibitor Maintenance Therapy for Newly Diagnosed Metastatic PAD
Golan T et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381(4):317-27. Abstract
Dr Dayyani
Module 1: Clinical Presentation and Prognosis of PAD; Recent Advances in Up-Front Treatment for Metastatic PAD
Conroy T et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817-25. Abstract
Conroy T et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. ASCO 2010;Abstract 4010.
Ohba A et al. Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial. ESMO 2023;Abstract 1616O.
Ozaka M et al. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Eur J Cancer 2023;181:135-44. Abstract
Von Hoff DD et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369(18):1691-703. Abstract
Wainburg ZA et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial. Lancet 2023;402(10409):1272-81. Abstract
Module 2: Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD
Go S-I et al. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). Eur J Cancer 2021;157:21-30. Abstract
Huh G et al. Gemcitabine plus nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: A multicenter, single-arm, open-label, phase 2 trial. Ther Adv Med Oncol 2021;13. Abstract
Neuzillet C et al. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol 2012;18(33):4533-41. Abstract
Sezgin Y et al. Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. Sci Rep 2025;15(1):11675. Abstract
Wang-Gillam A et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial. Lancet 2016;387(10018):545-57. Abstract
Zaniboni A et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: A GISCAD multicenter phase II study. Cancer Chemother Pharmacol 2012;69(6):1641-5. Abstract
Ms Kuhlman
Module 1: Clinical Presentation and Prognosis of PAD; Recent Advances in Up-Front Treatment for Metastatic PAD
Nichetti F et al. NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: A systematic review and meta-analysis. JAMA Netw Open 2024;7(1). Abstract
Wainberg ZA et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial. Lancet 2023;402(10409):1272-81. Abstract
Module 3: Importance of Palliative Care for Advanced PAD
Temel JS et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363(8):733-42. Abstract
Dr Philip
Module 4: Role of PARP Inhibitor Maintenance Therapy for Newly Diagnosed Metastatic PAD
Golan T et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381(4):317-27. Abstract
Kindler HL et al. Overall survival results from the POLO trial: A phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol 2022;40(34):3929-39. Abstract
Kindler HL et al. Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. ASCO 2019;Abstract LBA4.
Module 5: Promising Investigational Strategies for PAD
Bekaii-Saab TS et al. Adagrasib in advanced solid tumors harboring a KRASG12C mutation. J Clin Oncol 2023;41(25):4097-106. Abstract
Garrido-Laguna I et al. Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC). Gastrointestinal Cancers Symposium 2025;Abstract 722.
Kim D-W et al. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions. Future Oncol 2024;20(16):1057-67. Abstract
Philip PA et al. Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma. Clin Cancer Res 2022;28(12):2704-14. Abstract
Schram AM et al. Efficacy of zenocutuzumab in NRG1 fusion-positive cancer. N Engl J Med 2025;392(6):566-76. Abstract
Singhal A et al. Targeting KRAS in cancer. Nat Med 2024;30(4):969-83. Abstract
Strickler JH et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med 2023;388(1):33-43. Abstract